Greenwich LifeSciences, Inc.

NASDAQ:GLSI

Biotechnology

Healthcare
$20.58 -3.08%

-$0.74 today

Market cap
$302.08M
Beta
1.38
P/E (TTM)
-15.6
EPS (TTM)
-$1.49
52W Low $7.78High $34.10

Volume 0.71M

Average 0.14M

GLSI Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Greenwich LifeSciences, Inc.NASDAQ: GLSI

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $518.19K rose 4.3% year over year, ahead of the -26.5% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 20.7% from the prior quarter. Over 3 fiscal years it compounded at +12.5% a year.

Context

  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +3.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$518.19K-20.7% QoQ
Last fiscal yearDec 2025
$2.23M+3.4% YoY
LTMMar 2026
$2.36M-26.5% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.3%-100.0%-104.3 pp
1 year+3.4%-100.0%-103.4 pp
3-year CAGR+12.5%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
2.23M USD
Year-over-year change
+3.4%
4-year CAGR
+21.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How GLSI compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -26.5% is the 7th highest of 9, against a peer median of -1.7%.
  • Over three fiscal years its annual growth of +12.5% compares with a peer median of +2.7%.
GLSI Competitors
Selling, General & Admin for GLSI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGENAgenus Inc.LTM Mar 2026$45.53M USD-35.6%-12.4%36.8%
SEERSeer, Inc.LTM Mar 2026$40.57M USD-24.5%-6.8%269.8%
IRDOpus Genetics, Inc.LTM Mar 2026$21.57M USD+8.6%+44.6%180.0%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$18.6M CAD+58.0%+35.4%—
SRZNSurrozen, Inc.LTM Mar 2026$18.36M USD+21.1%-6.5%244.9%
IMMXImmix Biopharma, Inc.LTM Mar 2026$15.81M USD+34.6%+50.4%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$10.32M USD-12.0%-7.1%—
HURATuHURA Biosciences, Inc.LTM Mar 2026$3.55M USD-47.4%+11.8%—
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$2.36M USD-26.5%+12.5%—
Peer median (excluding GLSI) —-1.7%+2.7%212.5%

Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue3.61K3.61K3.61K3.61K1.78K
Gross Profit(3.61K)(3.61K)(3.61K)(3.61K)(1.78K)
Gross Margin—————
Research & Development3.56M6.48M7.7M15.48M17.22M
Selling, General & Admin1.04M1.56M1.63M2.15M2.23M
Operating Expenses4.59M8.04M9.32M17.63M19.45M
Depreciation & Amortization3.61K3.61K3.61K3.61K1.78K
EBITDA(4.57M)(7.82M)(8.89M)(17.41M)(19.36M)
EBITDA Margin—————
Operating Income(4.6M)(8.04M)(9.33M)(17.64M)(19.45M)
Operating Margin—————
Interest Income27.37K215.02K436.06K223.01K89.7K
Interest Expense00000
Other Income / Expenses27.37K215.02K436.06K223.01K89.7K
Income Before Tax(4.57M)(7.83M)(8.89M)(17.41M)(19.36M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(4.57M)(7.83M)(8.89M)(17.41M)(19.36M)
Net Margin—————
EPS (Basic)(0.35)(0.61)(0.69)(1.21)(1.43)
EPS (Diluted)(0.35)(0.61)(0.69)(1.21)(1.43)
Weighted Avg Shares12.94M12.91M12.85M13.01M13.53M
Weighted Avg Shares (Diluted)12.94M12.91M12.85M13.01M13.53M

Greenwich LifeSciences, Inc.

NASDAQ:GLSI

Intrinsic Alpha fair value

Locked

Current Price

$20.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.